Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Shares Gain After Prasugrel Drug Study (Japan)

This article was originally published in PharmAsia News

Executive Summary

Promising results from a large, late-stage clinical trial sent Daiichi Sankyo's share's skyrocketing 7.4 percent Monday, the company's biggest single gain since it went public on the Tokyo Stock Exchange in 2005. A late-stage study of 13,608 patients found prasugrel was more effective than market leader Plavix in preventing heart attacks. Results presented at the American Heart Association's yearly meeting showed only 9.9 percent of patients who took prasugrel suffered major cardiovascular events during the trial, compared to 12 percent of those on Plavix. The study, sponsored by Daiichi and co-developer Eli Lilly, also showed prasugrel was faster acting than Plavix. Recently, Daiichi and Lily halted two prasugrel trials, citing a need for dosing changes. The announcement made many insiders worry there might be serious risks associated with the drug. Although prasugrel did show a higher bleeding risk than Plavix, researchers say it should not be enough to prevent regulatory approval. (Click here for more - May Require Free Registration

You may also be interested in...

Radical Shake-Up In Store For Entire EU Pharma Legislation

The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.

EU Pharma Strategy Will Remove Barriers And Bolster Competition

The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.

Pfizer Faces 15-Year Wait On US Adrenalin Generic

Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts